Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes
the rate-limiting
step in NAD+ biosynthesis via salvage of NAM formed from
catabolism of NAD+ by proteins with NADase activity (e.g.,
PARPs, SIRTs, CD38). Depletion of NAD+ in aging, neurodegeneration,
and metabolic disorders is addressed by NAD+ supplementation.
Conversely, NAMPT inhibitors have been developed for cancer therapy:
many discovered by phenotypic screening for cancer cell death have
low nanomolar potency in cellular models. No NAMPT inhibitor is yet
FDA-approved. The ability of inhibitors to act as NAMPT substrates
may be associated with efficacy and toxicity. Some 3-pyridyl inhibitors
become 4-pyridyl activators or “NAD+ boosters”.
NAMPT positive allosteric modulators (N-PAMs) and boosters may increase
enzyme activity by relieving substrate/product inhibition. Binding
to a “rear channel” extending from the NAMPT active
site is key for inhibitors, boosters, and N-PAMs. A deeper understanding
may fulfill the potential of NAMPT ligands to regulate cellular life
and death.